In people with type 2 diabetes, Semaglutide is recommended as a supplement to diet and exercise to enhance glycemic control. For long-term weight management in adults who are obese (starting body mass index (BMI) 30 kg/m2) or overweight (initial BMI 27 kg/m2) and have at least one weight-related comorbidities, the higher-dose formulation of semaglutide is recommended as a supplement to diet and exercise. Semaglutide and tirzepatide (which share a similar mechanism of action) were considered to be more promising than earlier anti-obesity medications, however they were still less successful than bariatric surgery in a review of anti-obesity medicines.
Semaglutide and tirzepatide (which share a similar mechanism of action) were considered to be more promising than earlier anti-obesity medications, however they were still less successful than bariatric surgery in a review of anti-obesity medicines. Constipation, abdominal pain, headaches, fatigue, indigestion/heartburn, dizziness, bloating (abdominal distension), belching, low blood sugar (hypoglycemia) in people with type 2 diabetes, gas (flatulence), gastroenteritis, and gastroesophageal reflux disease are a few examples of potential side effects (GERD).
